SCHEMBL7130973

SCHEMBL7130973

CCC(C)COC(=O)c1ccc(O)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.76
ESR1 P03372 3/20 0.62
CA12 O43570 3/20 0.62
CA1 P00915 3/20 0.62
CA2 P00918 3/20 0.62
CA7 P43166 3/20 0.62
CA9 Q16790 3/20 0.62
CA14 Q9ULX7 3/20 0.62
ESR2 Q92731 2/20 0.62
ADRB2 P07550 2/20 0.59
ADRB1 P08588 2/20 0.59
ADRB3 P13945 2/20 0.59
ALDH1A1 P00352 3/20 0.59
TSHR P16473 2/20 0.59
CHRM1 P11229 1/20 0.59
SLC6A2 P23975 1/20 0.59
KDR P35968 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
MAPK1 P28482 2/20 0.56
LMNA P02545 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6937249 1.00 MAPT (0.76) MAPTESR1CA12CA1CA2
SCHEMBL7130965 1.00 MAPT (0.76) MAPTESR1CA12CA1CA2
SCHEMBL6934705 0.95 MAPT (0.69) MAPTESR1CA12CA1CA2
SCHEMBL8377627 0.95 MAPT (0.69) MAPTESR1CA12CA1CA2
SCHEMBL5368475 0.93 MAPT (0.86) MAPTESR1CA12CA1CA2
SCHEMBL4953172 0.92 MAPT (0.66) MAPTESR1CA12CA1CA2
SCHEMBL9456360 0.92 MAPT (0.66) MAPTESR1CA12CA1CA2
SCHEMBL9511839 0.89 MAPT (0.61) MAPTESR1CA12CA1CA2
SCHEMBL8956806 0.88 MAPT (0.78) MAPTESR1CA12CA1CA2
SCHEMBL9493542 0.88 MAPT (0.78) MAPTESR1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149388-A1 OPIOID ANTAGONIST FORMULATIONS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. 2023-05-18 US disclosed
WO-2021216450-A1 OPIOID ANTAGONIST FORMULATIONS EMERGENT PRODUCT DEVELOPMENTGAITHERSBURG INC. (US) 2021-10-28 WO disclosed
US-6666989-B1 Electrical and electro-optic apparatus comprising spaced glass panels having polyethers and electrodes on the interior surfaces, used as detectors, screens and in nonlinear optical apparatus QINETIQ LIMITED (GB) 2003-12-23 US disclosed
EP-1060226-A1 LIQUID CRYSTAL POLYMER DEVICES AND MATERIALS THE SECRETARY OF STATE FOR DEFENCE (GB) 2000-12-20 EP disclosed
WO-1999043763-A1 LIQUID CRYSTAL POLYMER DEVICES AND MATERIALS THE SECRETARY OF STATE FOR DEFENCE (GB) 1999-09-02 WO disclosed
EP-0274128-B1 Liquid-crystalline polymer IDEMITSU KOSAN CO (JP) 1999-03-31 EP disclosed
US-5324451-A Excellent response and memory DAINIPPON INK AND CHEMICALS, INC. (JP) 1994-06-28 US disclosed
US-5312564-A Halogen-containing, optically active liquid crystal compound and liquid crystal composition containing same CHISSO CORPORATION (JP) 1994-05-17 US disclosed
EP-0296571-B1 Method of producing a liquid crystal optical element IDEMITSU KOSAN CO (JP) 1994-03-30 EP disclosed
EP-0355772-B1 Liquid-crystalline copolymer IDEMITSU KOSAN CO (JP) 1993-12-29 EP disclosed
EP-0258898-A2 Liquid-crystalline polymer IDEMITSU KOSAN COMPANY LIMITED (JP) 1988-03-09 EP disclosed
US-4728458-A FERROELECTRIC AJINOMOTO CO., LTD. (JP) 1988-03-01 US disclosed
EP-0228703-A2 Ferroelectric liquid crystal polymer IDEMITSU KOSAN COMPANY LIMITED (JP) 1987-07-15 EP disclosed
EP-0197677-A2 Halogen-containing, optically active liquid crystal compound and liquid crystal composition containing same Chisso Corporation (JP) 1986-10-15 EP disclosed
EP-0191600-A2 Polyphenyl-based ester compounds and liquid crystal compositions containing same AJINOMOTO CO., INC. (JP) 1986-08-20 EP disclosed
EP-0188222-A2 Novel liquid cristalline compounds having substituents DAINIPPON INK AND CHEMICALS, INC. (JP) 1986-07-23 EP disclosed
US-4589996-A DISPLAY ELEMENTS;HIGH RESPONSE VELOCITY CHISSO CORPORATION (JP) 1986-05-20 US disclosed
US-4576732-A OPTICAL DISPLAYS HITACHI, LTD. (JP) 1986-03-18 US disclosed
EP-0136845-A2 Liquid crystalline carbonic acid esters and liquid crystal compositions containing the same Chisso Corporation (JP) 1985-04-10 EP disclosed
EP-0110299-A2 Smectic liquid crystal compounds and liquid crystal compositions HITACHI, LTD. (JP) 1984-06-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149388-A1 OPIOID ANTAGONIST FORMULATIONS OPRK1, OPRD1, OPRM1 MAPT 546/4885ESR1 2443/4885CA12 955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.